Intermolecular Reports Third Quarter and Nine Month 2018 Financial Results
SAN JOSE, Calif., Nov. 6, 2018 /PRNewswire/ -- Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for the third quarter and nine months ended September 30, 2018.
Q3 2018 Financial and Operational Highlights
-- Revenue of $7.9 million, which exceeded the company's guidance.
-- Program revenue increased 7% year-over-year to $7.4 million.
-- Adjusted EBITDA totaled $0.5 million, which exceeded the company's
guidance and marked the company's fifth consecutive quarter of positive
adjusted EBITDA.
-- Net loss totaled $(0.7) million, an improvement from net loss of $(1.8)
million in the same period a year ago.
-- Secured four program contracts during the period.
Recent Operational Highlights
-- Signed a major new program service agreement with a leading
semiconductor manufacturer during the fourth quarter of 2018. Management
expects a material revenue contribution in 2019.
Nine Month 2018 Financial and Operational Highlights
-- Revenue increased 3% to $27.3 million.
-- Program revenue increased 29% to a $26.0 million.
-- Total operating expenses decreased 30% to $20.5 million.
-- Adjusted EBITDA improved to $3.3 million from a loss of $(2.8) million
in the same period a year ago.
-- Net loss totaled $(0.8) million, a significant improvement from a net
loss of $(10.5) million in the same period a year ago.
-- Cash and investments increased $4.8 million from December 31, 2017 to
$30.6 million, or $0.62 per share, at September 30, 2018. The company
also continued to have no debt.
-- Secured nine program contracts during the period.
Management Commentary
"Our financial results for the third quarter exceeded our guidance for the period," said Intermolecular President and CEO Chris Kramer. "Q3 marked our fifth consecutive quarter of positive adjusted EBITDA, which we believe reflects the continued strength of our services business and consistent execution of our ongoing cost management initiatives. Looking at our financial results for the first nine months of 2018, our adjusted EBITDA reached the highest level in five years, which we believe reflects both strong demand for our services as well as a 30% reduction in operating expenses.
"While we do expect a slowdown in the fourth quarter due to the timing of certain program completions as well as a temporary delay in the scheduled commencement of a new program, we are encouraged by the recent major new program service agreement we secured in Q4 with a leading semiconductor manufacturer. With this new relationship as well as our increasing momentum in additional new programs and extensions, coupled with the improved operational efficiencies that we have been implementing, we believe we are well-positioned for 2019 and beyond. Additionally, the share repurchase program we announced today is a reflection of our confidence in the business and our commitment to maximizing shareholder value."
Third Quarter of 2018 Financial Results
Revenue for the third quarter of 2018 was $7.9 million, a decrease of 20% from $9.8 million in the second quarter of 2018, and a decrease of 9% from $8.6 million in the same period a year ago. Program revenue was $7.4 million, a 21% decrease from $9.4 million in the second quarter of 2018, and a 7% increase from $6.9 million in the same period a year ago.
Gross profit for the third quarter of 2018 was $5.8 million (74% of total revenue), a 1% increase from $5.7 million (67% of total revenue) in the same period a year ago.
Total operating expenses for the third quarter of 2018 were $6.7 million, flat compared to the second quarter of 2018, and a decrease of 13% compared to $7.7 million in the same period a year ago.
Net loss for the third quarter of 2018 totaled $(0.7) million, or $(0.01) per basic and diluted share, compared to net income of $0.5 million, or $0.01 per basic and diluted share in the second quarter of 2018, and an improvement from a net loss of $(1.8) million, or $(0.04) per basic and diluted share in the same period a year ago.
Non-GAAP net loss, which excludes stock-based compensation expense, for the third quarter of 2018 totaled $(0.5) million, or $(0.01) per basic and diluted share, compared to non-GAAP net income of $0.7 million, or $0.01 per basic and diluted share in the second quarter of 2018, and an improvement from a non-GAAP net loss of $(1.6) million, or $(0.03) per basic and diluted share in the same period a year ago.
Adjusted EBITDA for the third quarter of 2018 totaled $0.5 million, compared to $1.8 million in the second quarter of 2018, and an improvement from an adjusted EBITDA of $0.1 million in the same period a year ago.
Cash and investments totaled $30.6 million at the end of third quarter of 2018, a decrease of $0.7 million compared to $31.3 million at the end of second quarter of 2018. The company had no debt at quarter end.
Nine Month 2018 Financial Results
Revenue for the first nine months of 2018 was $27.3 million, an increase of 3% from $26.7 million in the same period a year ago. Program revenue was $26.0 million, an increase of 29% from $20.2 million in the same period a year ago.
Gross profit for the first nine months of 2018 was $19.0 million (70% of total revenue), a 4% increase from $18.2 million (68% of total revenue) in the same period a year ago.
Total operating expenses for the first nine months of 2018 was $20.5 million, a decrease of 30% compared to $29.2 million in the same period a year ago.
Net loss for the first nine months of 2018 totaled $(0.8) million, or $(0.02) per basic and diluted share, an improvement from a net loss of $(10.5) million, or $(0.21) per basic and diluted share in the same period a year ago.
Non-GAAP net loss for the first nine months of 2018 totaled $(0.2) million, or $(0.00) per basic and diluted share, an improvement from a non-GAAP net loss of $(9.3) million, or $(0.19) per basic and diluted share in the same period a year ago.
Adjusted EBITDA for the first nine months of 2018 totaled $3.3 million, an improvement from an adjusted EBITDA loss of $(2.8) million in the same period a year ago.
2018 Financial Outlook
The following statements are based on Intermolecular's current expectations for the fourth quarter ending December 31, 2018. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below. Intermolecular does not plan to update, nor does it undertake any obligation to update, this outlook in the future.
-- Revenue is projected to be in the range of $5.2 million to $5.8 million;
-- Net loss is projected to be between $(2.8) million and $(3.2) million,
or $(0.06) per share (based on approximately 49.8 million shares
expected to be outstanding);
-- Non-GAAP net loss is projected to be between $(2.4) million and $(2.8)
million, or $(0.05) per share and $(0.06) per share, respectively (based
on approximately 49.8 million shares expected to be outstanding); and,
-- Adjusted EBITDA loss is projected to be between $(1.8) million and
$(2.2) million.
Intermolecular reports revenue, cost of revenue, gross margin, operating income (loss), net income (loss) and earnings (loss) per share in accordance with U.S. generally accepted accounting principles (GAAP) and additionally on a non-GAAP basis. A reconciliation of the non-GAAP financial measures with the most directly comparable GAAP measures, as well as a description of the items excluded from the non-GAAP measures, is included in the financial statements portion of this press release. Please refer to "Reconciliation of GAAP to Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Loss to Non-GAAP Net Loss" below.
Conference Call
Intermolecular will host a conference call and simultaneous audio-only webcast today (November 6, 2018) at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss these results. The call will be hosted by Intermolecular President and CEO Chris Kramer and CFO Bill Roeschlein.
U.S. dial-in number: (877) 251-1860
International dial-in number: (224) 357-2386
Conference ID: 9991865
Please call the conference telephone number five to ten minutes prior to start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact Liolios Group at (949) 574-3860.
A live and archived webcast (audio only) of the call will be available on Intermolecular's website for up to 30 days after the call.
About Intermolecular, Inc.
Intermolecular(®) is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation in the 21(st) century for a wide range of industries including semiconductors, consumer electronics, automotive and aerospace. With its substantial materials expertise, accelerated learning and experimentation platform, and information and analytics infrastructure, Intermolecular has a ten-year track record helping leading companies accelerate and de-risk materials innovation. Learn more at www.intermolecular.com.
"Intermolecular" and the Intermolecular logo are registered trademarks; all rights reserved.
Forward-Looking Statements
Statements made in this press release and the earnings call referencing the press release that are not statements of historical fact are forward-looking statements. Forward-looking statements are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "expects," "believes," "plans," "intends," "projects" and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this document are based on current beliefs, assumptions and expectations, speak only as of the date of this document and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and generally beyond Intermolecular's control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: our ability to productize our workflows with existing and future customers; expectations regarding our future revenue, cash flow and GAAP and non-GAAP net income or loss; financial condition; the ability of our new business model to generate profits and long-term shareholder returns; the extent to which technology developed in collaboration with our customers will continue to remain on the critical path and have significant value for such customers and us as well as the industry as a whole; and anticipated growth in our current markets through expansion of existing customer programs and the entry into other engagements with new customers. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: our ability to execute on our strategy, prove our business model and remain technologically competitive in rapidly evolving industry conditions; commercial acceptance of our HPC platform and methodology as effective R&D tools; our ability to achieve and sustain profitability; the ability of our customers to achieve their announced product roadmaps in a timely manner; the extent to which we are able to successfully extend and expand relationships with existing customers; our ability to manage the growth of our business; the rapid technology changes and volatility of the customers and industries we serve; our potential need for future capital to finance our operations; and other risks described in our most recent annual report on Form 10-K as updated by our quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission available at www.sec.gov, particularly in the sections titled "Risk Factors." All forward-looking statements are based on management's current estimates, projections and assumptions, and we assume no obligation to update them.
Non-GAAP Financial Measures
To supplement the financial data presented on a GAAP basis, we also disclose certain non-GAAP financial measures, which exclude the effect of stock-based compensation expense. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than non-GAAP financial information disclosed by other companies. These results should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. We believe that our non-GAAP financial information provides useful information to management and investors regarding financial and business trends relating to our financial condition and results of operations because the non-GAAP measures exclude charges that management considers to be outside of Intermolecular's core operating results. We believe that the non-GAAP measures of revenue, cost of net revenue, gross profit, gross margin, operating (loss) income, net (loss) income, earnings per share and net (loss) income per share, viewed in combination with our financial results calculated in accordance with GAAP, provide investors with additional perspective and a more meaningful understanding of our ongoing operating performance. In addition, management uses these non-GAAP measures to review and assess financial performance, to determine executive officer incentive compensation and to plan and forecast performance in future periods.
Corporate Contact
Bill Roeschlein
Intermolecular, Inc.
Chief Financial Officer
bill.roeschlein@intermolecular.com
(408) 582-5415
Investor Contact
Matt Glover or Najim Mostamand, CFA
Liolios Group, Inc.
IMI@liolios.com
(949) 574-3860
Intermolecular, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts, Unaudited)
Three Months Ended Nine Months Ended September 30,
September 30,
2018 2017 2018 2017
Revenue:
Program revenue $
7,354 $
6,869 $
25,975 $
20,160
Licensing and royalty revenue 508 1,753 1,364 6,495
Total revenue 7,862 8,622 27,339 26,655
Cost of revenue:
Cost of program revenue 2,054 2,864 8,286 8,106
Cost of licensing and royalty revenue 4 11 8 303
Total cost of revenue 2,058 2,875 8,294 8,409
Gross profit 5,804 5,747 19,045 18,246
Operating expenses:
Research and development 4,463 4,835 12,551 17,328
Sales and marketing 692 874 2,346 3,285
General and administrative 1,581 2,000 5,615 7,225
Restructuring charges 1,351
Total operating expenses 6,736 7,709 20,512 29,189
Loss from operations (932) (1,962) (1,467) (10,943)
Other income (expense):
Interest income (expense), net 168 70 413 182
Other income (expense), net 78 64 241 243
Total other income (expense), net 246 134 654 425
Loss before provision for income
taxes (686) (1,828) (813) (10,518)
Provision for income taxes 1 1
Net loss $
(686) $
(1,828) $
(814) $
(10,519)
Net loss per share, basic and diluted $
(0.01) $
(0.04) $
(0.02) $
(0.21)
Weighted-average number of shares
used in computing net loss per
share, basic and diluted 49,746,082 49,554,701 49,667,518 49,543,014
Intermolecular, Inc.
Condensed Consolidated Balance Sheets
(In thousands, Unaudited)
As of September 30, 2018 As of December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents $
6,889 $
6,090
Short-term investments 23,759 18,060
Total cash, cash equivalents and short-
term investments 30,648 24,150
Accounts receivable 3,330 5,519
Prepaid expenses and other current
assets 949 1,069
Total current assets 34,927 30,738
Long-term investments 1,657
Materials inventory 2,752 2,781
Property and equipment, net 3,497 5,913
Intangible assets, net 2,141 2,620
Other assets 542 600
Total assets $
43,859 $
44,309
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $
752 $
928
Accrued liabilities 917 865
Accrued compensation and employee
benefits 2,602 2,535
Deferred revenue 289 941
Total current liabilities 4,560 5,269
Other long-term liabilities 2,737 2,967
Total liabilities 7,297 8,236
Stockholders' equity:
Common stock 50 50
Additional paid-in capital 215,606 214,796
Accumulated other comprehensive loss (19) (35)
Accumulated deficit (179,075) (178,738)
Total stockholders' equity 36,562 36,073
Total liabilities and stockholders'
equity $
43,859 $
44,309
Intermolecular, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands, Unaudited)
Nine Months Ended September 30,
2018 2017
Cash flows from operating activities:
Net loss $
(814) $
(10,519)
Adjustments to reconcile net loss to net
cash used in operating
activities:
Depreciation, amortization and accretion 3,514 5,369
Stock-based compensation 624 1,221
Loss on disposal of property and equipment 70
Changes in operating assets and
liabilities:
Accounts receivable 2,666 1,587
Prepaid expenses and other assets 177 663
Materials inventory 57 391
Accounts payable (304) 688
Accrued and other liabilities (220) 370
Deferred revenue (652) 485
Net cash provided by operating activities 5,048 325
Cash flows from investing activities:
Purchase of investments (21,968) (15,505)
Redemption of investments 18,151 20,014
Purchase of property and equipment (620) (705)
Proceeds from sale of equipment 1 12
Net cash (used in) provided by investing
activities (4,436) 3,816
Cash flows from financing activities:
Payment of capital leases (13)
Proceeds from exercise of common stock
options 187
Net cash (used in) provided by financing
activities 187 (13)
Net increase (decrease) in cash and cash
equivalents 799 4,128
Cash and cash equivalents at beginning of
period 6,090 5,759
Cash and cash equivalents at end of period $
6,889 $
9,887
Intermolecular, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts and percentages, Unaudited)
Three Months Ended
Nine Months Ended
September 30, September 30,
2018 2017 2018 2017
GAAP cost of net revenue $
2,058 $
2,875 $
8,294 $
8,409
Stock-based compensation expense (a) (33) (38) (125) (144)
Non-GAAP cost of net revenue $
2,025 $
2,837 $
8,169 $
8,265
GAAP gross profit $
5,804 $
5,747 $
19,045 $
18,246
Stock-based compensation expense (a) 33 38 125 144
Non-GAAP gross profit $
5,837 $
5,785 $
19,170 $
18,390
As a percentage of net revenue:
GAAP gross margin 73.8% 66.7% 69.7% 68.5%
Non-GAAP gross margin 74.2% 67.1% 70.1% 69.0%
GAAP operating loss $
(932) $
(1,962) $
(1,467) $
(10,943)
Stock-based compensation expense (a):
- Cost of net revenue 33 38 125 144
- Research and development 69 61 183 306
- Sales and marketing 22 28 73 97
- General and administrative 18 115 243 674
Non-GAAP operating loss $
(790) $
(1,720) $
(843) $
(9,722)
GAAP net loss $
(686) $
(1,828) $
(814) $
(10,519)
Stock-based compensation expense (a) 142 242 624 1,221
Non-GAAP net loss $
(544) $
(1,586) $
(190) $
(9,298)
GAAP net loss $
(686) $
(1,828) $
(814) $
(10,519)
Interest (income) expense, net (168) (70) (413) (182)
Provision for taxes 1 1
Depreciation, amortization, impairments and
accretion 1,212 1,772 3,905 5,369
Restructuring charges (b) 1,351
Stock-based compensation expense (a) 142 242 624 1,221
Adjusted EBITDA $
500 $
116 $
3,303 $
(2,759)
Shares used in computing GAAP basic and
diluted earnings per share 49,746,082 49,554,701 49,667,518 49,543,014
GAAP earnings per share:
Basic and diluted net loss per share $
(0.01) $
(0.04) $
(0.02) $
(0.21)
Shares used in computing Non-GAAP basic and
diluted earnings per share 49,746,082 49,554,701 49,667,518 49,543,014
Non-GAAP earnings per share:
Basic and diluted net loss per share $
(0.01) $
(0.03) $
(0.00) $
(0.19)
(a) Stock-based compensation reflects
expense recorded relating to
stock-based awards. The Company
excludes this item when it
evaluates the continuing
operational performance of the
Company, as management believes
this provides it a meaningful
understanding of its core
operating performance.
(b) Restructuring charges incurred in
connection with a reduction in
headcount primarily comprised of
employee severance and benefit
costs.
Intermolecular, Inc.
Fourth Quarter 2018 Outlook
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss
(In thousands, except per share amounts, Unaudited)
GAAP net loss range
$(2,800) - $(3,200)
Stock-based compensation
$400 - $400
Non-GAAP net loss range
$(2,400) - $(2,800)
GAAP and Non-GAAP diluted shares 49,800
GAAP net loss per share range
$(0.06) - $(0.06)
Non-GAAP net loss per share range
$(0.05) - $(0.06)
View original content to download multimedia:http://www.prnewswire.com/news-releases/intermolecular-reports-third-quarter-and-nine-month-2018-financial-results-300745011.html
SOURCE Intermolecular, Inc.
